ADCendo
Adcendo ApS is a global clinical-stage biotech company dedicated to developing highly differentiated first and best-in-class antibody-drug conjugates (ADCs) for targeted cancer treatment. The company focuses on innovative ADC targets such as uPARAP and Tissue Factor, aiming to bring new treatments to patients with high unmet medical needs. With a strong leadership team and collaborations with top-tier investors, Adcendo is advancing its pipeline through clinical development and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
ADCendo
Products
Clinical-stage ADC targeting uPARAP (uPARAP‑directed ADC)
A first-in-class ADC designed to target the recycling endocytic receptor uPARAP, progressed into first-in-human clinical studies for mesenchymal and other cancers with high uPARAP expression.
ADC candidate targeting Tissue Factor with Topo‑1 payload (TF‑directed Topo‑1 ADC)
A differentiated anti‑Tissue Factor ADC incorporating a Topoisomerase‑1 inhibitor payload and next-generation linker chemistry, progressed toward clinical initiation and subject to an out‑/in‑licensing arrangement for regional rights.
Clinical-stage ADC targeting uPARAP (uPARAP‑directed ADC)
A first-in-class ADC designed to target the recycling endocytic receptor uPARAP, progressed into first-in-human clinical studies for mesenchymal and other cancers with high uPARAP expression.
ADC candidate targeting Tissue Factor with Topo‑1 payload (TF‑directed Topo‑1 ADC)
A differentiated anti‑Tissue Factor ADC incorporating a Topoisomerase‑1 inhibitor payload and next-generation linker chemistry, progressed toward clinical initiation and subject to an out‑/in‑licensing arrangement for regional rights.
Services
Evaluation and licensing of next-generation linker–payload platforms to support ADC development programs, including option agreements to nominate additional targets.
Partnership-driven translational research with academic and clinical centres for target expression studies, biomarker development and preclinical model evaluations.
Evaluation and licensing of next-generation linker–payload platforms to support ADC development programs, including option agreements to nominate additional targets.
Partnership-driven translational research with academic and clinical centres for target expression studies, biomarker development and preclinical model evaluations.
Expertise Areas
- Antibody-drug conjugate development
- Target discovery and validation (endocytic receptors)
- Preclinical in vivo oncology models (PDX and xenograft)
- Early-phase clinical development (Phase I/II) in oncology
Key Technologies
- Antibody-drug conjugates (ADC)
- Linker–payload platforms
- Topoisomerase‑1 inhibitor payloads
- Recycling endocytic receptor targeting (uPARAP)
News & Updates
Adcendo will present data on its ADCs ADCE-T02 and ADCE-D01, demonstrating their efficacy and target expression in cancer models.
The company appointed Laura Shawver, Ph.D., as Chair of the Board and Roy Baynes, M.D., Ph.D., as independent director, along with other leadership updates.
Adcendo announced the successful closing of a EUR 51 million Series A financing led by Novo Seeds and Ysios Capital.
Dr. Ottesen brings extensive clinical development expertise in oncology and ADCs to lead Adcendo's clinical strategy.
Adcendo licenses Duality’s DITAC linker/payload platform for its lead uPARAP-ADC program.
The company expands its collaboration with Duality to evaluate additional novel ADC targets.
Adcendo will present data on its ADCs ADCE-T02 and ADCE-D01, demonstrating their efficacy and target expression in cancer models.
The company appointed Laura Shawver, Ph.D., as Chair of the Board and Roy Baynes, M.D., Ph.D., as independent director, along with other leadership updates.
Adcendo announced the successful closing of a EUR 51 million Series A financing led by Novo Seeds and Ysios Capital.
Dr. Ottesen brings extensive clinical development expertise in oncology and ADCs to lead Adcendo's clinical strategy.
Adcendo licenses Duality’s DITAC linker/payload platform for its lead uPARAP-ADC program.
The company expands its collaboration with Duality to evaluate additional novel ADC targets.